Comparative Pharmacology
Head-to-head clinical analysis: ARAKODA versus QUININE SULFATE.
Head-to-head clinical analysis: ARAKODA versus QUININE SULFATE.
ARAKODA vs QUININE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Quinine sulfate is a blood schizonticide effective against the asexual erythrocytic forms of Plasmodium spp. It interferes with the parasite's ability to digest hemoglobin, leading to accumulation of toxic heme and parasite death. Quinine also has mild analgesic and antipyretic effects, and may depress cardiac conduction and contractility.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
324 mg orally every 8 hours for 7 days (for treatment of chloroquine-resistant falciparum malaria, in combination with other antimalarials).
None Documented
None Documented
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Terminal elimination half-life: 18 hours (range 16-21 hours) in healthy adults; prolonged in renal impairment (up to 25-30 hours) and severe hepatic impairment.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Renal: 20% unchanged; hepatic metabolism (CYP3A4, CYP2C9) accounts for 80% with metabolites (primarily 3-hydroxyquinine) excreted renally and fecally. Biliary excretion is minor (<5%).
Category C
Category D/X
Antimalarial
Antimalarial